Atopic dermatitis is manifested by various clinical signs and a complex disturbance of immunity. Although it is mainly driven by a biased T helper 2 (Th2) cell response, other T cell subsets, including the OX40 pathway, contribute to its development. Rocatinlimab is a fully human monoclonal antibody targeting the OX40 receptor on activated T cells that inhibits pathogenic T cells and restores T cell balance. This commentary reviews the results of two phase 3 studies – ROCKET-IGNITE and ROCKET-HORIZON – published in The Lancet by Emma Guttman-Yassky and colleagues in adult patients with atopic dermatitis. Studies have investigated rocatinlimab as a new therapy for this disease.